Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28269329 | 0.92 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL27312324 | 0.90 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL15942130 | 0.85 | CA14 (0.38) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL29290727 | 0.85 | CA14 (0.48) | CA14CA12CA1CA7 | |
| SCHEMBL11421139 | 0.82 | CA14 (0.59) | CA14CA12CA1 | |
| SCHEMBL14157466 | 0.82 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL3414844 | 0.81 | HDAC6 (0.36) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL2608081 | 0.80 | CA14 (0.49) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL503444 | 0.80 | CA14 (0.53) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL28355374 | 0.80 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858974-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2022-07-20 | — | — | EP | disclosed |
| EP-3489220-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3489220-B1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-11084779-B2 | Cationic lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2021-08-10 | — | — | US | disclosed |
| US-10961181-B2 | — | — | 2021-03-30 | — | — | US | disclosed |
| US-20200199064-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20200085957-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2020-03-19 | — | — | US | disclosed |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2019-10-15 | — | — | US | disclosed |
| EP-2998289-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-3489220-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | Nitto Denko Corporation (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-20170081663-A1 | RETINOID-LIPID DRUG CARRIER | NITTO DENKO CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-2998289-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-2718261-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-9011903-B2 | Cationic lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2858974-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | Nitto Denko Corporation (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2718261-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | Nitto Denko Corporation (JP) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013185116-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | PAYNE JOSEPH E (US) | 2013-12-12 | — | — | WO | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | SGMS1, SGMS2, S1PR3 | CA14 1115/4885HDAC6 1140/4885HDAC1 613/4885 |
| US-20200085957-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | LIPA, SGMS2, SGMS1 | CA14 2130/4885HDAC6 940/4885HDAC1 2043/4885 |
| US-20200199064-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | SGMS1, SGMS2, CERT1 | CA14 1002/4885HDAC6 1576/4885HDAC1 841/4885 |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | LIPA, SGMS2, SGMS1 | CA14 2130/4885HDAC6 940/4885HDAC1 2043/4885 |
| US-20170081663-A1 | RETINOID-LIPID DRUG CARRIER | RXRA, RXRG, LRAT | CA14 4224/4885HDAC6 1215/4885HDAC1 2109/4885 |
| US-10961181-B2 | — | DEGS1, SGMS1, C5 | CA14 1018/4885HDAC6 3412/4885HDAC1 1882/4885 |
| US-11084779-B2 | Cationic lipids for therapeutic agent delivery formulations | SGMS1, SGMS2, CERT1 | CA14 1002/4885HDAC6 1576/4885HDAC1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.